A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Summary

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2157299 in participants with hepatocellular carcinoma.

Timeline

Start

2014-08-08

Primary completion

2017-06-30

Completion

2021-02-18

Outcome

Missed primary endpoint

registry analysis (superiority test); 150 mg Galunisertib Monotherapy vs 400 mg Sorafenib + Placebo Therapy; p = 0.837 NCT02178358 ↗

registry analysis (superiority test); 150 mg Galunisertib + 400 mg Sorafenib Therapy vs 400 mg Sorafenib + Placebo Therapy; p = 0.704 NCT02178358 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Galunisertib	Small molecule	150 mg	Oral
Subject	Sorafenib	Small molecule	400 mg	Oral

Indications